Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

PD-1-based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphoma

Blood blood.2025030151.

https://doi.org/10.1182/blood.2025030151

Published: 2025

Includes: Supplemental data

Journal Articles

Allogeneic stem cell transplant results in t-cell prolymphocytic leukemia (T-PLL): A collaborative multi-center study cohort

Blood (2025) 146 (Supplement 1): 1054.

https://doi.org/10.1182/blood-2025-1054

Published: 2025

Journal Articles

CXCL9 is a predictive biomarker of survival with IFNγ-targeted therapy in adult HLH patients

William Johnson, Joseph Rocco, Rikita Patel, Adrianna Herskovits, Elena Mead, Jae Park, Alison Moskowitz, Zachary Epstein-Peterson, Robert Stuver, Neil Bapodra, Rabeya Molla, Andrew Intlekofer, Jennifer Lue, Lia Palomba, Ariela Noy, Jasmine Zain, Colette Owens, Lynnette Henshaw, Paola Ghione, Efrat Luttwak, Pallawi Torka, Andrew Zelenetz, Philip Caron, Anita Kumar, Lorenzo Falchi, Natasha Galasso, Paul Hamlin, Alexander Boardman, Kevin David, Raphael Steiner, Nivetha Ganesan, Tiffany Chang, Zainab Shahid, Wenbin Xiao, Annamaria Ballweg, Alina Markova, Mark Geyer, Lauren Banaszak, Roni Shouval, Sergio Giralt, Gregory Goldgof, Jodi Mones, Jeffrey Zwicker, Rekha Parameswaran, Avi Leader, Cy R. Wilkins, Simon Mantha, Jeffrey Cohen, Jessica Durkee-Shock, Matthew Sedlock, Bita Shakoory, Irini Sereti, Miguel-Angel Perales, Gilles Salles, Santosha Vardhana, Joseph Oved, Steven Horwitz

Blood (2025) 146 (Supplement 1): 2996.

https://doi.org/10.1182/blood-2025-2996

Published: 2025

Journal Articles

Outcomes of second-line systemic therapy for relapsed or refractory peripheral T-cell lymphomas: A single-center, retrospective analysis

Zachary Epstein-Peterson, Nivetha Ganesan, Ellie Casper, Tiffany Chang, Ahmet Dogan, Ozgur Can Eren, Natasha Galasso, Paola Ghione, Kelly Hannigan, Varun Iyengar, William Johnson, Jason Krastein, Katie Ksanznak, Alison Moskowitz, Brittney Munayiri, Benedetta Sordi, Robert Stuver, Jasmine Zain, Steven Horwitz

Blood (2025) 146 (Supplement 1): 5412.

https://doi.org/10.1182/blood-2025-5412

Published: 2025

Journal Articles

Impact of DUSP22 and TP63 rearrangements in patients with ALK-negative ALCL treated with frontline BV-CH(E)P

Blood (2025) 146 (Supplement 1): 5410.

https://doi.org/10.1182/blood-2025-5410

Published: 2025

Journal Articles

Frontline chemotherapy for CD30+ non-ALCL peripheral T-cell lymphoma a multi-center retrospective analysis

Blood (2025) 146 (Supplement 1): 3641.

https://doi.org/10.1182/blood-2025-3641

Published: 2025

Journal Articles

A multicenter real-world analysis (RWA) of primary cutaneous anaplastic large cell lymphoma (PCALCL) treated in the era of targeted therapies

Deepa Jagadeesh, Stefan Barta, Seunghee Margevicius, Jonathan Brammer, Jeanette Comstock, Pingfu Fu, Rahul Mishra, Montreh Tavakkoli, Alma Habib, Imran Nizamuddin, Tiffany Chang, Melissa Pulitzer, Cesar Virgen, Sharina Macapagal, Madiha Iqbal, N. Nora Bennani, Frederick Lansigan, Neha Mehta-Shah, Zachary Epstein-Peterson

Blood (2025) 146 (Supplement 1): 5433.

https://doi.org/10.1182/blood-2025-5433

Published: 2025

Journal Articles

Integrated dissociated and spatial single-cell profiling reveals that HDAC inhibition restores anti-PD-1 sensitivity in Hodgkin lymphoma by disrupting monocyte-Hodgkin-reed-sternberg cell-driven immunosuppressive niches.

Blood (2025) 146 (Supplement 1): 150.

https://doi.org/10.1182/blood-2025-150

Published: 2025

Journal Articles

Angioimmunoblastic Versus Non-Angioimmunoblastic Nodal T-Follicular Helper Cell Lymphomas: Single Center Retrospective Analysis on 208 Cases

Blood (2024) 144 (Supplement 1): 4451.

https://doi.org/10.1182/blood-2024-210657

Published: 2024

Journal Articles

Final Response and Survival Results from a Phase II Trial of Pembrolizumab and Entinostat in Relapsed/Refractory Hodgkin Lymphoma

Blood (2024) 144 (Supplement 1): 3053.

https://doi.org/10.1182/blood-2024-210053

Published: 2024

Journal Articles

Pembrolizumab for Front-Line Treatment of Extranodal NK/T-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 3068.

https://doi.org/10.1182/blood-2024-206398

Published: 2024

Journal Articles

Pembrolizumab Maintenance Instead of Autologous Hematopoietic Cell Transplantation for Patients with Relapsed or Refractory Hodgkin Lymphoma in Complete Response after Pembrolizumab, Gemcitabine, Vinorelbine, and Liposomal Doxorubicin

Blood (2024) 144 (Supplement 1): 569.

https://doi.org/10.1182/blood-2024-202537

Published: 2024

Journal Articles

Survival and Therapeutic Outcomes in T-Cell Prolymphocytic Leukemia (T-PLL): A Collaborative Multi-Center Study Cohort

Blood (2024) 144 (Supplement 1): 982.

https://doi.org/10.1182/blood-2024-194242

Published: 2024

Journal Articles

Pembrolizumab and Involved Site Radiation Therapy Alone As an Alternative to Transplant in Patients with Localized Failure Following Chemotherapy for Hodgkin Lymphoma: A Prospective Multicenter Phase II Study

Blood (2024) 144 (Supplement 1): 4434.

https://doi.org/10.1182/blood-2024-210689

Published: 2024

Journal Articles

Improved Outcomes for Primary Refractory Classical Hodgkin Lymphoma: A Retrospective Analysis

Blood (2024) 144 (Supplement 1): 4429.

https://doi.org/10.1182/blood-2024-203857

Published: 2024

Journal Articles

Dual-Targeted Therapy with Ruxolitinib Plus Duvelisib for T-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 463.

https://doi.org/10.1182/blood-2024-206462

Published: 2024

Journal Articles

Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial

Steven W. Pipe, Peter Collins, Christophe Dhalluin, Gili Kenet, Christophe Schmitt, Muriel Buri, Víctor Jiménez-Yuste, Flora Peyvandi, Guy Young, Johannes Oldenburg, Maria Elisa Mancuso, Kaan Kavakli, Anna Kiialainen, Sonia Deb, Markus Niggli, Tiffany Chang, Michaela Lehle, Karin Fijnvandraat

Blood (2024) 143 (14): 1355–1364.

https://doi.org/10.1182/blood.2023021832

Published: 2024

Includes: Supplemental data

Journal Articles

Outcomes for Patients with Classical Hodgkin Lymphoma Who Relapse after Autologous Stem Cell Transplant in the Era of Novel Therapies

Robert Stuver, Esther Drill, Nivetha Ganesan, Kelsey Baron, Ellie Casper, Tiffany Chang, Sanjal H. Desai, Ayo S Falade, Natasha Galasso, Alex F. Herrera, Matthew G. Mei, Reid W. Merryman, Ivana Micallef, Harsh Shah, Alison Moskowitz

Blood (2023) 142 (Supplement 1): 3069.

https://doi.org/10.1182/blood-2023-182143

Published: 2023

Journal Articles

Efficacy of Brentuximab Vedotin Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma with and without Pre-Transplant Exposure to Novel Agents

Blood (2023) 142 (Supplement 1): 3062.

https://doi.org/10.1182/blood-2023-182318

Published: 2023

Journal Articles

Emicizumab Prophylaxis in Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Primary Analysis of the HAVEN 7 Study

Steven Pipe, Peter Collins, Christophe Dhalluin, Gili Kenet, Christophe Schmitt, Muriel Buri, Víctor Jiménez-Yuste, Flora Peyvandi, Guy Young, Johannes Oldenburg, Maria Elisa Mancuso, Kaan Kavakli, Anna Kiialainen, Tiffany Chang, Michaela Lehle, Markus Niggli, Karin Fijnvandraat

Blood (2023) 142 (Supplement 1): 505.

https://doi.org/10.1182/blood-2023-177963

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

PD-1-based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphoma

Allogeneic stem cell transplant results in t-cell prolymphocytic leukemia (T-PLL): A collaborative multi-center study cohort

CXCL9 is a predictive biomarker of survival with IFNγ-targeted therapy in adult HLH patients

Outcomes of second-line systemic therapy for relapsed or refractory peripheral T-cell lymphomas: A single-center, retrospective analysis

Impact of DUSP22 and TP63 rearrangements in patients with ALK-negative ALCL treated with frontline BV-CH(E)P

Frontline chemotherapy for CD30+ non-ALCL peripheral T-cell lymphoma a multi-center retrospective analysis

A multicenter real-world analysis (RWA) of primary cutaneous anaplastic large cell lymphoma (PCALCL) treated in the era of targeted therapies

Integrated dissociated and spatial single-cell profiling reveals that HDAC inhibition restores anti-PD-1 sensitivity in Hodgkin lymphoma by disrupting monocyte-Hodgkin-reed-sternberg cell-driven immunosuppressive niches.

Angioimmunoblastic Versus Non-Angioimmunoblastic Nodal T-Follicular Helper Cell Lymphomas: Single Center Retrospective Analysis on 208 Cases

Final Response and Survival Results from a Phase II Trial of Pembrolizumab and Entinostat in Relapsed/Refractory Hodgkin Lymphoma

Pembrolizumab for Front-Line Treatment of Extranodal NK/T-Cell Lymphoma

Pembrolizumab Maintenance Instead of Autologous Hematopoietic Cell Transplantation for Patients with Relapsed or Refractory Hodgkin Lymphoma in Complete Response after Pembrolizumab, Gemcitabine, Vinorelbine, and Liposomal Doxorubicin

Survival and Therapeutic Outcomes in T-Cell Prolymphocytic Leukemia (T-PLL): A Collaborative Multi-Center Study Cohort

Pembrolizumab and Involved Site Radiation Therapy Alone As an Alternative to Transplant in Patients with Localized Failure Following Chemotherapy for Hodgkin Lymphoma: A Prospective Multicenter Phase II Study

Improved Outcomes for Primary Refractory Classical Hodgkin Lymphoma: A Retrospective Analysis

Dual-Targeted Therapy with Ruxolitinib Plus Duvelisib for T-Cell Lymphoma

Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial

Outcomes for Patients with Classical Hodgkin Lymphoma Who Relapse after Autologous Stem Cell Transplant in the Era of Novel Therapies

Efficacy of Brentuximab Vedotin Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma with and without Pre-Transplant Exposure to Novel Agents

Emicizumab Prophylaxis in Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Primary Analysis of the HAVEN 7 Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only